

Special Issue

New Insights into Upper Tract Urothelial Carcinoma: What Changed?

Message from the Guest Editors

Upper-tract urothelial carcinoma (UTUC) is an aggressive disease that is managed by radical or organ-sparing surgery. Upper-tract urothelial cancer (UTUC) lacks high-quality evidence to appraise current patterns of presentation, diagnosis, treatment and outcomes as a result of disease rarity and patient heterogeneity. The goal is to obtain a curative setting after diagnosis and primary surgery for UTUC, which can be achieved through accurate and close FU. The impact of standardized regular surveillance on better oncological prognosis has already been investigated in several malignancies, including primary urothelial cancer of the bladder. This again considers the objective for regular surveillance in UTUC to achieve a better outcome based on early recurrence detection. To achieve this, the implementation of prospective randomized studies with standardized strict follow-up protocols a key imperative role. This Special Issue presents up-to-date summaries related to the pathogenesis, diagnosis, prognostic assessment and management of UTUC.

Guest Editors

Dr. Sisto Perdonà

Istituto Nazionale Tumori di Napoli, IRCCS "Fondazione G. Pascale", Via M. Semmola, 80131 Naples, Italy

Dr. Antonio Tufano

Department of Maternal-Child and Urological Sciences, Policlinico Umberto I Hospital, Sapienza University Rome, 00162 Rome, Italy

Deadline for manuscript submissions

closed (30 June 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/173757

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).